Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "systemic lupus erythematosus (SLE)"

Results from Belimumab Safety Study

Michele B. Kaufman, PharmD, BCGP  |  July 13, 2018

In a long-term extension study, belimumab proved safe, demonstrating low organ damage accrual in SLE patients treated for up to nine years…

Neutrophils & B Cells Create Unique Antibodies in Lupus Patients

Lara C. Pullen, PhD  |  July 11, 2018

NETs or LL37-DNA complexes may serve as future targets for SLE therapy. In a recent study, researchers identified a link between neutrophils and NETs, and the activation of self-reactive B cells. Their study describes a neutrophil-B cell interaction unique to lupus…

Lupus & Cognitive Dysfunction: No Apparent Link to Inflammation

Lara C. Pullen, PhD  |  June 27, 2018

Does cognitive dysfunction in SLE patients result from persistent inflammation characterized by ongoing disease activity? Recent research examining this question found no inflammatory mechanism associated with cognitive dysfunction in this patient population, underscoring previous research findings…

Is Chemical Exposure Linked to DNA Methylation Dysregulation in SLE Patients?

Carina Stanton  |  June 5, 2018

Could your lupus patients benefit from limiting exposure to chemicals at home and in the medical environment? It’s a strong possibility, according to the preliminary findings of a research team investigating DNA methylation disruption in patients with SLE…

Insight into the Downregulation of NK Cells in SLE Patients

Lara C. Pullen, PhD  |  June 4, 2018

New research suggests the downregulation of CD3ζ contributes to the altered function of NK cells in SLE patients, which may contribute to the increased risk of viral infections in these patients…

Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes

Reuters Staff  |  May 1, 2018

NEW YORK (Reuters Health)—Subcutaneous belimumab improves outcomes in anti-dsDNA-positive hypocomplementemic patients with systemic lupus erythematosus (SLE), according to results from a Phase 3 randomized, controlled trial. Intravenous belimumab is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with active, autoantibody-positive SLE who are receiving standard…

New Classification Criteria for SLE: Proposed ACR/EULAR Criteria aim for high sensitivity & specificity

Susan Bernstein  |  December 15, 2017

SAN DIEGO—The proposed classification criteria for systemic lupus erythematosus (SLE), supported but not yet approved by the ACR and EULAR, were debuted on Nov. 7 at the 2017 ACR/ARHP Annual Meeting. An international steering committee developed and validated the criteria, with patient input and the consensus of more than 150 global SLE experts. Rheumatology researchers…

The Pop Star Effect & Lupus: Celebrity Cred May Help Raise Awareness of Rheumatic Disease

Richard Quinn  |  December 15, 2017

This year, Selena Gomez underwent a kidney transplant as a result of damage from living with lupus. But how can this celebrity story aid rheumatologists? Many see it as an opportunity to raise awareness or create a dialogue with primary care physicians. But for lupus patients, it can be a reminder for them to take control of their own wellbeing, according to rheumatologist Susan Manzi, MD, MPH…

European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat

Michele B. Kaufman, PharmD, BCGP  |  November 29, 2017

Subcutaneous belimumab has been approved in the EU to help treat patients with active autoantibody-positive SLE…

2017 in Review: Key Findings in Basic Science Highlighted at the ACR/ARHP Annual Meeting

Thomas R. Collins  |  November 14, 2017

During the ACR/ARHP Annual Meeting, Richard Pope, MD, highlighted some of the top scientific literature on rheumatic disease from 2017. The review session discussed research on the effects of microglia on the central nervous system of SLE patients, the role of adenosine in osteoarthritis and more…

  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 12
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences